A phase II neoadjuvant trial of anastrozole, fulvestrant and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

Endocrine therapy in patients with breast cancer can be limited by the problem of resistance. Preclinical studies suggest that complete blockade of the estrogen receptor (ER) combined with inhibition of the epidermal growth factor receptor (EGFR) can overcome endocrine resistance. We tested this hyp...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Breast Cancer Res Treat
Главные авторы: Massarweh, Suleiman, Tham, Yee L, Huang, Jian, Sexton, Krystal, Weiss, Heidi, Tsimelzon, Anna, Bayer, Amanda, Rimawi, Mothaffar, Cai, Wei Yen, Hilsenbeck, Susan, Fuqua, Suzanne, Elledge, Richard
Формат: Artigo
Язык:Inglês
Опубликовано: 2011
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4477822/
https://ncbi.nlm.nih.gov/pubmed/21792626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-011-1679-8
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы